67 related articles for article (PubMed ID: 26653551)
1. Modification of sPD1 with CRT induces potent anti-tumor immune responses in vitro and in vivo.
Wang G; Li Z; Tian H; Wu W; Liu C
Biomed Pharmacother; 2015 Dec; 76():57-64. PubMed ID: 26653551
[TBL] [Abstract][Full Text] [Related]
2. Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice.
Qin Y; Han Y; Cao C; Ren Y; Li C; Wang Y
Cancer Biol Ther; 2011 Mar; 11(6):574-80. PubMed ID: 21270533
[TBL] [Abstract][Full Text] [Related]
3. Whole-cell vaccine coated with recombinant calreticulin enhances activation of dendritic cells and induces tumour-specific immune responses.
Wu H; Han Y; Qin Y; Cao C; Xia Y; Liu C; Wang Y
Oncol Rep; 2013 Feb; 29(2):529-34. PubMed ID: 23166014
[TBL] [Abstract][Full Text] [Related]
4. A mouse monoclonal antibody specific for calreticulin.
Wang G; Yang J; Liu C
Hybridoma (Larchmt); 2012 Oct; 31(5):382-5. PubMed ID: 23098307
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
6. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of recombinant calreticulin fragment 39-272: implications for immunobiological activities of calreticulin in health and disease.
Hong C; Qiu X; Li Y; Huang Q; Zhong Z; Zhang Y; Liu X; Sun L; Lv P; Gao XM
J Immunol; 2010 Oct; 185(8):4561-9. PubMed ID: 20855873
[TBL] [Abstract][Full Text] [Related]
8. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.
Liu C; Lu Z; Xie Y; Guo Q; Geng F; Sun B; Wu H; Yu B; Wu J; Zhang H; Yu X; Kong W
Immunol Lett; 2018 Aug; 200():33-42. PubMed ID: 29894719
[TBL] [Abstract][Full Text] [Related]
9. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules.
Wang HT; Lee HI; Guo JH; Chen SH; Liao ZK; Huang KW; Torng PL; Hwang LH
Int J Cancer; 2012 Jun; 130(12):2892-902. PubMed ID: 21805477
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7.
Rangel-Colmenero BR; Gomez-Gutierrez JG; Villatoro-Hernández J; Zavala-Flores LM; Quistián-Martínez D; Rojas-Martínez A; Arce-Mendoza AY; Guzmán-López S; Montes-de-Oca-Luna R; Saucedo-Cárdenas O
Viral Immunol; 2014 Nov; 27(9):463-7. PubMed ID: 25216057
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
Rüttinger D; Li R; Poehlein CH; Haley D; Walker EB; Hu HM; Fox BA
J Immunother; 2008 Jan; 31(1):43-51. PubMed ID: 18157011
[TBL] [Abstract][Full Text] [Related]
13. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
14. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen.
Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF
Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cellular immunity by antibodies against calreticulin.
Qiu X; Hong C; Zhong Z; Li Y; Zhang T; Bao W; Xiong S; Gao XM
Eur J Immunol; 2012 Sep; 42(9):2419-30. PubMed ID: 22685035
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
18. [Anti-tumor immune responses of nanoemulsion-encapsulated MHS vaccine].
Ge W; Sun YJ; Li Y; Zhang SH; Zhang XM; Huang Y; Hu PZ; Sui YF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 May; 24(5):457-60. PubMed ID: 18466701
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis.
Cheng L; Tang X; Liu L; Peng J; Nishiura K; Cheung AK; Guo J; Wu X; Tang HY; An M; Zhou J; Cheung KW; Wang H; Guan X; Wu Z; Chen Z
MAbs; 2015; 7(3):620-9. PubMed ID: 25692916
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
